Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2019 07:30 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 3rd, 2019

WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
September 10, 2019 07:30 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases on September 24, 2019

WALTHAM, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
August 26, 2019 09:30 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 5th, 2019

WALTHAM, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
August 13, 2019 10:01 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Society of Nephrology (ASN) Kidney Week 2019

WALTHAM, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
August 07, 2019 07:30 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update

Phase 2 cystic fibrosis clinical trial IND is open in the U.S., protocol endorsed by the Cystic Fibrosis Foundation (CFF) Initiated a Phase 2 clinical trial for ELX-02 in cystinosis in Canada and...
August 05, 2019 08:00 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial for ELX-02 in Cystinosis

Dr. Paul Goodyer, Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, is the principal investigator in the Phase 2 clinical trial On track to report top...
July 31, 2019 12:12 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cystic Fibrosis Foundation (CFF)

On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis and cystinosis in the U.S., Europe, Israel and Canada in 2019 Company to host webcast and conference call...
July 17, 2019 07:30 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals to Present at the 39th Annual Canaccord Genuity Growth Conference on August 8th, 2019

WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
July 16, 2019 08:00 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on August 7, 2019

WALTHAM, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
June 24, 2019 16:01 ET | Source: Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WALTHAM, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq: ELOX) today announced the closing of its underwritten public offering of 3,833,334 shares of its...